Product information and disease descriptionProduct descriptionProduct information
Product comparison
6 evidence topics · 10 sources
Diazoxide: the only FDA-approved drug labeled for hypoglycemia from inoperable islet cell tumors or extrapancreatic malignancy
Ersodetug compared with current medical therapies: manufacturer statements on site of action and limitations of comparators
Everolimus: labeled indication in pancreatic neuroendocrine tumors and hyperglycemia incidence
Tumor-directed agents with neuroendocrine tumor indications: lutetium Lu 177 dotatate and cabozantinib
Hypoglycemia control across systemic therapies in malignant insulinoma: Mayo Clinic cohort
“This study retrospectively analyzed 57 patients treated for malignant insulinoma at Mayo Clinic sites between 1992 and 2024, focusing on the efficacy of systemic therapies in improving hypoglycemic control and survival outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpelisib: off-label use in insulin- or proinsulin-producing tumors
“We present a case series describing the effectiveness and tolerability of the phosphatidylinositol 3-kinase inhibitor alpelisib in 2 women with metastatic insulin-producing or proinsulin-producing tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the first patient, the proportion of glucose readings <54 mg/dL fell from 2.3% (95% CI, 2.1-2.4) to 0.2% (95% CI, 0.2%-0.3%), and the rate ratio was 0.087 (95% CI, 0.086-0.089).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to high cost and off-label use, the process of obtaining alpelisib was complex and took several months for the first patient and 2 years for the second patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct comparisons of ersodetug with other therapies
No evidence found.